ArticleVaccine2016
Beyond efficacy: The full public health impact of vaccines.
Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pooled it
- Prevalence of COVID-19 vaccine hesitancy in Brazil: a systematic review and meta-analysis.Frontiers in public health · 2025Pooled it
- Community effectiveness of indoor spraying as a dengue vector control method: A systematic review.PLoS neglected tropical diseases · 2017Pooled it
- Pooled it
- Effect of Influenza Vaccination on the Disease Severity and Viral Load Among Adult Outpatients and Inpatients.Vaccines · 2025Article
- Quasi-experimental methods for pharmacoepidemiology: difference-in-differences and synthetic control methods with case studies for vaccine evaluation.American journal of epidemiology · 2024Article
- Economic burden of dengue in urban Bangladesh: A societal perspective.PLoS neglected tropical diseases · 2023Article
- Economic evaluations of immunization programs as an indispensable tool for policymakers.BMC health services research · 2023Article
- Vaccine hesitancy in Malawi: a threat to already-made health gains.Annals of medicine and surgery (2012) · 2023Article
- Public Health Impacts of Vaccines for COVID-19 and Beyond: Opportunities to Overcome Technical and Regulatory Barriers for Randomized Trials.American journal of public health · 2023Article
- Serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates among Croatian adults during a fifteen-year period (2005-2019).Croatian medical journal · 2022Article
- Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination.Human vaccines & immunotherapeutics · 2020Article
- Routine infant vaccination of pneumococcal conjugate vaccines has decreased pneumonia across all age groups in Northern Spain.Human vaccines & immunotherapeutics · 2020Article
- Arboviruses: A global public health threat.Vaccine · 2020Article
- How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future.Journal of market access & health policy · 2020Review
- Article
- Public Health-Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union.Emerging infectious diseases · 2019Article
- Building the evidence base for dengue vector control: searching for certainty in an uncertain world.Pathogens and global health · 2018Review
- Estimating the full public health value of vaccination.Vaccine · 2017Article
- The public health value of vaccines beyond efficacy: methods, measures and outcomes.BMC medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
There is an active discussion in the public health community on how to assess and incorporate, in addition to safety and measures of protective efficacy, the full public health value of preventive vaccines into the evidence-based decision-making process of vaccine licensure and recommendations for public health use. The conference "Beyond efficacy: the full public health impact of vaccines in addition to efficacy measures in trials" held in Annecy, France (June 22-24, 2015) has addressed this issue and provided recommendations on how to better capture the whole public health impact of vaccines. Using key examples, the expert group stressed that we are in the midst of a new paradigm in vaccine evaluation, where all aspects of public health value of vaccines beyond efficacy should be evaluated. To yield a wider scope of vaccine benefits, additional measures such as vaccine preventable disease incidence, overall efficacy and other outcomes such as under-five mortality or non-etiologically confirmed clinical syndromes should be assessed in addition to traditional efficacy or effectiveness measurements. Dynamic modelling and the use of probe studies should also be considered to provide additional insight to the full public health value of a vaccine. The use of burden reduction and conditional licensure of vaccines based on collection of outcome results should be considered by regulatory agencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.